NantHealth and NantOmics Announce GPS Cancer® Platform May Improve Clinical Trial Design of Combination Strategies by Identifying Previously Unrecognized Cancer Type Specific Associations between Immunoregulatory Molecules and Genomic Mutations

Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 6, 2020 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in...

read more


7:02 pm MST |  Jun 8, 2018  |  BioCentury  |  Product Development POC FOR CYTOKINES Cytokines are emerging as a logical combination partner to boost PD-1 responses by Emily Cukier, Senior Writer

read more

The CLIA certification and CAP accreditation ensures the highest quality test results from the NantOmics lab to help improve cancer outcomes and will support the Cancer Cancer Breakthroughs 2020 mission in its war on cancer

CULVER CITY, Calif. – April 19, 2016 – NantOmics, LLC, the leader in molecular diagnostics and member of the NantWorks ecosystem of families, today announced that its laboratories have been certified by the U.S. Department of Health and Human Services'...

read more

Contact Us

Fill out my online form.